Literature DB >> 25523979

Autoantibody-defined risk for Type 1 diabetes mellitus in a general population of schoolchildren: results of the Karlsburg Type 1 Diabetes Risk Study after 18 years.

A-M Till1, H Kenk2, I Rjasanowski3, R Wassmuth4, U Walschus5, W Kerner3, M Schlosser5.   

Abstract

AIMS: To investigate the occurrence of diabetes-associated autoantibodies and cumulative Type 1 diabetes risk over 18 years in a general population of schoolchildren.
METHODS: In the Karlsburg Type 1 Diabetes Risk Study, 11 986 schoolchildren from north-eastern Germany without a family history of diabetes were screened for glutamic acid decarboxylase antibodies, insulinoma-associated antigen-2 antibodies and insulin autoantibodies by radioligand binding assay. Those children found to be autoantibody-positive were invited to follow-up examinations and HLA-DQB1 genotyping, and were followed for progression to Type 1 diabetes.
RESULTS: At first follow-up, 119 children had single and 36 children had multiple autoantibodies. Of the multiple autoantibody-positive children, 33 had at least one diabetes-associated HLA-DQB1 allele (*02 and/or *0302). A total of 26 children progressed to Type 1 diabetes, of whom 22 had multiple autoantibodies. The male-to-female ratio of those who progressed to Type 1 diabetes was 1.6. The positive predictive value of multiple autoantibodies was 61.1% compared with only 23.7% for diabetes-associated HLA-DQB1 genotypes among all those who were autoantibody-positive. The cumulative risk was 59.7% after 10 years and 75.1% after 18 years for children with multiple autoantibodies compared with 1.2 and 22.6%, respectively, for children with single autoantibodies (P<0.001). Among the three examined autoantibodies, insulinoma-associated antigen-2 antibodies conferred the highest risk.
CONCLUSIONS: The diabetes risk in schoolchildren with multiple autoantibodies was similar to the risk reported in other studies for genetically preselected probands; thus, a combined autoantibody-based screening could effectively identify at-risk individuals from the general population for future intervention trials.
© 2014 The Authors. Diabetic Medicine © 2014 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25523979     DOI: 10.1111/dme.12677

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  2 in total

1.  Autoantibodies against islet cell antigens in children with type 1 diabetes mellitus.

Authors:  Bi-Wen Cheng; Fu-Sung Lo; An-Mei Wang; Chen-Mei Hung; Chi-Yu Huang; Wei-Hsin Ting; Mei-Ore Yang; Chao-Hsu Lin; Chia-Ching Chen; Chiung-Ling Lin; Yi-Lei Wu; Yann-Jinn Lee
Journal:  Oncotarget       Date:  2018-02-19

2.  Activation of CD4+ and CD8+ T-lymphocytes by insulin and GAD in patients with type 1 or 2 diabetes mellitus.

Authors:  Borros Arneth
Journal:  Endocr Connect       Date:  2017-10-06       Impact factor: 3.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.